## **Risk Characterisation**

## In this guide

## In this guide

- 1. Background and Introduction Garcinia cambogia oral consumption
- 2. Data from authoritative bodies Garcinia cambogia oral consumption
- 3. Chemical composition Garcinia cambogia oral consumption
- 4. ANSES Garcinia cambogia oral consumption
- 5. AESAN Garcinia cambogia oral consumption
- 6. Australian TGA Garcinia cambogia oral consumption
- 7. <u>BfR (German Federal Institute for Risk Assessment) Garcinia cambogia oral</u> consumption
- 8. EFSA Garcinia cambogia oral consumption
- 9. Health Canada Garcinia cambogia oral consumption
- 10. NCCIH Garcinia cambogia oral consumption
- 11. Data from literature search Garcinia cambogia oral consumption
- 12. Human data Garcinia cambogia oral consumption
- 13. Hepatotoxic case reports Garcinia cambogia oral consumption
- 14. Animal studies Garcinia cambogia oral consumption
- 15. Exposure Garcinia cambogia oral consumption
- 16. Uncertainties Garcinia cambogia oral consumption
- 17. Risk Characterisation Garcinia cambogia oral consumption
- 18. Questions to the Committee Garcinia cambogia oral consumption
- 19. Abbreviations Garcinia cambogia oral consumption
- 20. References Garcinia cambogia oral consumption

## This is a discussion paper. It does not reflect the views of the Committee. It should not be cited.

196. The presence of HCA in food supplements is considered medicinal according to the UK MHRA (see paragraph 8). From the Brief market analysis described in the Exposure section it is clear that some products are medicinal.

Data from nutrivigilance programs/schemes of authoritative bodies and literature have reported the following adverse effects following consumption of supplements containing *G. cambogia*: hepatic, digestive (pancreatitis), cardiac and muscular (rhabdomyolysis) damage, psychiatric, metabolic disorders, as well as drug-drug interactions. However, the mode of action of *G. cambogia* and its extracts have yet to be fully elucidated.